Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We thank Parker and Wright for engaging in this roundtable debate in such a spirited way. The 'Pharmacogenetic [test] to Avoid Loss of Hearing' (PALOH) Trial is the first time a genetic point of care test has been applied in the acute neonatal setting; therefore, it is not surprising that questions have been raised which require debate, discussion and clarification. Parker and Wright misattribute several assumptions to the roundtable authors, which we would like to clarify here. Since they raise wider questions about the PALOH trial itself, several of the roundtable discussants have made a joint response.

Original publication

DOI

10.1136/medethics-2020-107048

Type

Journal article

Journal

Journal of medical ethics

Publication Date

02/2021

Volume

47

Pages

117 - 118

Addresses

CELS, University of Southampton, Southampton, UK a.m.lucassen@soton.ac.uk.

Keywords

Humans, Anti-Bacterial Agents, Morals, Infant, Infant, Newborn, Genetic Testing, Biomarkers